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Class solutions for SABR-VMAT for high-risk
prostate cancer with and without elective
nodal irradiation
Sarah O. S. Osman1*, Prakash Jeevanandam2, Nithya Kanakavelu2, Denise M. Irvine2, Ciara A. Lyons1, Suneil Jain1,3,
Alan R. Hounsell1,2 and Conor K. McGarry1,2
Abstract
Background: The purpose of this study is to find the optimal planning settings for prostate SABR-VMAT for
high-risk prostate cancer patients irradiated to prostate only (PO) or prostate and pelvic lymph nodes (PPLN).
Methods: For 10 patients, plans using 6MV flattened, flattening-filter-free (FFF) 6MV (6 F) and FFF 10MV (10 F)
photon beams with full and partial arc arrangements were generated and compared. The prescribed dose was
40Gy to the prostate with 25Gy to the PLN in 5 fractions. Plans were then evaluated for PTV coverage, dose fall-off,
and OAR doses. The number of monitor units and the treatment delivery times were also compared. Statistical
differences were evaluated using a paired sample Wilcoxon signed rank test with a significance level of 0.05%.
Results: A total of 150 plans were generated for this study. Acceptable PO plans were obtained using single arcs,
while two arcs were necessary for PPLN. All plans were highly conformal (CI ≥1.3 and CN ≥0.90) with no significant
differences in the PTV dose coverage. 6MV plans required significantly longer treatment time and had higher dose
spillage compared to FFF plans. Superior plans were obtained using 10 F 300° partial arcs for PO with the lowest
rectal dose, dose spillage and the shortest treatment times. For PPLN, 6 F and 10 F plans were equivalent.
Conclusions: SABR-VMAT with FFF photon beams offers a clear benefit with respect to shorter treatment delivery
times and reduced dose spillage. Class solutions using a single 10 F 300° arc for PO and two 10 F or 6 F partial 300°
arcs for PPLN are proposed.
Keywords: High-risk prostate cancer, SABR, VMAT, Flattening-filter-free (FFF), Pelvic lymph nodes irradiation
Introduction
Stereotactic ablative body radiation therapy (SABR) has
been introduced as an attractive alternative to conventional
external beam radiation therapy techniques for prostate
cancer patients [1–4]. In contrast with conventional tech-
niques, SABR allows the delivery of fewer treatment frac-
tions with higher dose per fraction (hypo-fractionation).
Due to the potentially low alpha-beta ratio for the prostate
(high sensitivity to fraction size), hypo-fractionation is
thought to improve the therapeutic ratio for prostate radi-
ation therapy (RT), i.e., improving tumour control rates
while maintaining similar normal tissue biological effective
dose compared to conventional fractionation regimens
[5, 6]. Prostate SABR using volumetric modulated arc
therapy (VMAT) provides highly conformal plans, with
excellent tumour coverage and organs at risk (OARs)
sparing [7, 8]. One major advantage for VMAT over
conventional techniques is the shorter treatment times.
SABR-VMAT with flattening-filter free (FFF) photon
beams has been reported to be safe and effective [4, 9].
The high dose rates possible with FFF beams and the
reduced leakage and scatter dose to the patient are the
main reasons behind the increased use in SABR-VMAT for
prostate [8–10] and prostate and pelvic lymph nodes [11].
At the Northern Ireland Cancer Centre, we are preparing
for a randomized feasibility study evaluating Stereotactic
PrOstate RadioTherapy in high-risk localised prostate
cancer with or without elective nodal irradiation (SPORT
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High-Risk Trial) (http://www.hra.nhs.uk/news/research-
summaries/sport-high-risk-trial/\#sthash.Bn1ByfDP.dpuf).
Little is known about optimal planning techniques for
SABR-VMAT for prostate cancer, especially when pelvic
lymph nodes are treated electively. In preparation for the
clinical introduction of SABR-VMAT through SPORT, we
conducted this planning study in search of a class solution
to standardize our treatment planning process. In this
work, we systematically compared the use of 6MV flat-
tened photon beam, FFF 6MV (6 F) and FFF 10MV (10 F)
beams in the treatment of prostate only (PO) and prostate
and pelvic lymph nodes (PPLN) in SABR-VMAT settings.
Different arc arrangements were also investigated to arrive
at optimal parameters for each trial arm (i.e. PO or PPLN).
To the best of our knowledge, we are the first to investi-
gate and report on the feasibility of SABR-VMAT using
FFF photons with different energies and/or arc arrange-
ments to treat prostate and prostate and pelvic lymph
nodes.
Materials and methods
Anonymized data sets from ten previously treated pros-
tate cancer patients were selected for this study. Patients
had been instructed to use enemas and follow a drinking
protocol prior to imaging. CT scans with 2.5 mm slice
thickness were available (from below the upper third of
the femur to the top of L4).
Contouring and planning for SABR
Contouring was aided by fusing patients’ diagnostic MRI
scans with their planning CT scans in the Varian Eclipse
treatment planning system (TPS) version 13.5 (Eclipse,
Varian Medical Systems, Palo Alto, CA, USA). Three
clinical target volumes (CTV) were defined; 1) prostate
and proximal 10 mm of seminal vesicles (SV) CTV(P),
2) remaining SV CTV(SV), 3) pelvic lymph nodes
CTV(LN). The planning target volumes (PTVs) were
constructed to create two distinct PTVs; 1) PTV(P)
which is the CTV(P) expanded with 5 mm margins in all
directions except posteriorly (3 mm margin) 2) PTV(SV/
LN) consisting of the CTV(SV) + CTV(LN) + 7 mm iso-
tropic margin. Organs at risk (OARs) contoured were;
bladder, rectum, sigmoid colon, bowel, femoral heads,
and penile bulb. The prostatic urethra and neurovascular
bundles were also contoured with reference to both the
diagnostic MR and to standard anatomical references.
All planning was conducted in Eclipse TPS using the
Progressive Resolution Optimization (v.13.5) and Acuros
XB dose calculation algorithm (v.13.5) for a Varian
TrueBeam-STx Linac with a HD MLC. The dose calcula-
tion grid size used was 2.5 mm and the heterogeneity
correction and jaw tracking settings were enabled. A
subset of plans, were recalculated using 1.25 mm grid
size to assess the effect of using a finer grid size on dose
and optimization time.
Treatment planning and planning objectives
Plans were generated utilizing 10 F and 6 F as well as 6
MV flattened photon beams. Maximum dose rates were
used for each energy, 2400, 1400, and 600MU/min for
10 F, 6 F and 6MV, respectively. Several arc arrange-
ments were investigated. Single VMAT arcs were used
for PO plans [7, 8] while, after initial investigations for
PPLN plans, dosimetrically acceptable plans were only
achieved using two VMAT arcs.
Prostate only plans
Each data set was planned using three arc arrangements;
– One full 360° arc (FA).
– One partial arc 300° arc (210→ 150°; PA300).
– One partial arc 210° arc (255→ 105°; PA210) [7].
The prescribed dose was 40Gy for the CTV(P) and
36.25Gy for the PTV(P) given simultaneously in 5 frac-
tions. Detailed planning objectives and constraints for
targets and OARs are given in Table 1.
Prostate and pelvic lymph nodes plans
For prostate and pelvic lymph nodes planning, after ini-
tial investigations of several arc combinations, two arc
arrangements were investigated further;
– Two full arcs (2FA).
– Two partial 300° arcs (210→ 150° and 150→ 210°;
2PA300).
Similar to PO plans, 40Gy was prescribed to the CTV(P)
and 36.25Gy to PTV(P). Additionally, 25Gy was pre-
scribed to the PTV(SV/LN) to be delivered simultaneously
in 5 fractions. Dose objectives and constraints are also pre-
sented in Table 1.
The equivalent dose as 2Gy fractions (EQD2Gy) from a
hypo-fractionated course for tumours and OARs could
be calculated using the equation: EQD2Gy ¼ D
α
βþd
α
βþ2
h i
,
where D is the total dose given at dose d per fraction.
This hypo-fractionated dose regime corresponds to a
CTV(P) EQD2Gy of 108.6Gy, PTV(P) EQD2Gy of 90.6Gy
α
β ¼ 1:5Gy
 
, a normal tissue late effect EQD2Gy of
74.3Gy αβ ¼ 3Gy
 
, and an acute toxicity EQD2Gy of
52.1Gy αβ ¼ 10Gy
 
.
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Plan analysis, patient specific QA and statistical analysis
For the PTVs, the near maximum dose D2% and near
minimum dose D98% were recorded. Several dose metrics
were assessed for each OAR. Additionally, dose conform-
ity index (CI): volumeof 95% isodosePTV volume [12], conformation number
(CN): volumeof the PTV receiving 95% isodose
2
PTV volumevolumeof 95% isodose
 
[12], heterogeneity
index (HI): dose received by the hottest 2cc of PTVprescribed dose , were evaluated.
Population-averaged dose-volume histograms (DVHs)
for the PTVs and selected OARs are presented. Medium
and low-dose spillage outside the PTVs (R50 and R25) were
also assessed for each plan: Rx¼Volx%presPTV volume , where Volx% pres is
the tissue (body) volume receiving at least x% of the PTV
prescribed dose [13]. Patient specific size parameters were
also recorded and analysed for correlation with dose spill-
age (Additional file 1: Appendix I). The number of
monitor units (MUs) and estimated treatment delivery
times were also assessed.
For a subset of PO and PPLN plans, pre-treatment
dose verification was conducted using OCTAVIUS-4D
phantom consisting of a motorized cylindrical phantom
with a ±360° angular range (PTW, Freiburg, Germany)
[14]. For this investigation, a PTW OCTAVIUS 729 2D
array was inserted into the centre of the phantom. The
detector size is 0.5 × 0.5 × 0.5 cm3 (maximum field size =
27 × 27 cm2, centre to centre spacing = 10mm). Moreover,
30 plans representing high dose region, were delivered to
a PTW OCTAVIUS 1000 SRS 2D array (300° partial arcs
PO plans). The detector size is 2.3 mm× 2.3 mm×
0.5 mm. The detector spacing in the inner area (maximum
field size = 5.5 cm × 5.5 cm) is 2.5 mm centre-to-centre
and in the outer area is 5 mm centre-to-centre (maximum
field size = 10 cm× 10 cm).
A 3D gamma analysis was conducted using Verisoft
software version (6.2) which creates 3D dose maps from
the multiple 2D doses obtained [15]. Global gamma cri-
teria (passing rates: 3%/3 mm ≥ 97% and 2%/2 mm ≥ 90%)
were used with a 10% minimum dose threshold [16].
Statistics
Volume data distributions were normal for some structures
and non-normal for others; therefore, median values and
interquartile ranges [Q1–Q3] were presented. Statistical
analysis was conducted in MATLAB (v. 8.4-R2014b) using
the non-parametric two-sided paired-sample Wilcoxon
signed rank test as our dosimetric data was not normally
distributed. As multiple comparisons were conducted, the
significance level was set at p ≤ 0.005 for PO plan compari-
sons and p ≤ 0.01 for PPLN plans.
Results
A total of 150 plans were generated for this study. There
was no significant difference in the PTV dose coverage
using all energies and arc arrangements compared. CTV
and PTV objectives and constraints were met in all PO
and PPLN plans as shown in Tables 2 and 3. Comparing
a 2.5 mm dose calculation grid size with 1.25 mm re-
vealed only negligible differences in dose with the largest
difference in PTV (P) dose of ≤1.4% in D98% and D2% in
all cases (PO and PPLN). Five and six fold increase in
calculation time for PO and PPLN plans, respectively,
was observed when using a 1.25 mm grid size as op-
posed to 2.5 mm; therefore using a calculation grid size
of 2.5 mm was favoured in this study (Additional file 1:
Appendix II). Population-averaged DVHs are presented
in Fig. 1 and Additional file 2: Figure S1. In all following
analysis, 10 F plans were used as a reference for
comparisons.
Table 1 Dose-volume requirements and constraints adopted
for planning study
Targets Optimal
requirements
Mandatory
CTV(P)
Px1 = 40Gy
D98% ≥ 100% Px1 ≥100% dose
to ≥95 − 97%
PTV(P)
Px2 = 36.25Gy
D99% ≥95% Px2
V42Gy≤ 2%
≥95% dose to ≥98% volume
V42.8Gy ≤ 2%
PTV(SV/LN)a
Px3 = 25Gy
D99% ≥95% Px3 ≥95% dose to ≥98% volume
V107%
b≤ 2%
OARs Optimal Mandatory
Bladder V18.1Gy <40%
V37Gy < 5 cc V37Gy <10 cc
Rectum V18.1Gy <50%
V29Gy <20%
V36Gy <1 cc
Sigmoid V18.1Gy <50%
V29Gy <20%
V36Gy <1 cc
Bowel V15Gy <78 cc V15Gy <158 cc
V20Gy <17 cc V20Gy <110 cc
V22.5Gy <14 cc V22.5Gy <28 cc
V25Gy <0.5 cc V25Gy <1 cc
Femoral heads V14.5Gy <5%
Penile bulb V29.5Gy <50%
Prostatic urethra V42Gy < 50%
Neurovascular
bundle
V38Gy <50%
Testes Avoidance structure
aFor prostate and lymph nodes (PPLN) plans only, bEvaluated for a structure
[(PTV_Px3) - (PTV_Px2 + 10 mm margin)], Px prescription dose, OARs organs at risk,
VXGy volume receiving dose X in Gy, DX% the dose received by X% of the volume
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Table 2 Dose metrics for the PTV; median and ranges and statistical outcomes for different energies and arc arrangements for prostate only (PO) plans
Structure FA PA300 PA210
Volume (cc) 10 F 6 F 6MV 10 F 6 F 6MV 10 F 6 F 6MV
HI 1.05 1.04 1.05 1.05 1.05 1.04* 1.05 1.05 1.05
(1.05–1.05) (1.04–1.05) (1.04–1.05) (1.05–1.05) (1.04–1.05) (1.04–1.05) (1.05–1.06) (1.05–1.06) (1.05–1.06)
CI 1.18 1.17 1.18 1.17 1.17 1.17 1.18 1.17 1.17
(1.17–1.19) (1.15–1.19) (1.15–1.19) (1.16–1.19) (1.16–1.19) (1.16–1.21) (1.17–1.21) (1.16–1.20) (1.16–1.20)
CN 0.93 0.93 0.92 0.92 0.92 0.91 0.91ɫ 0.91 0.91
(0.92–0.93) (0.92–0.94) (0.92–0.93) (0.91–0.93) (0.91–0.93) (0.91–0.92) (0.91–0.92) (0.91–0.92) (0.90–0.91)
R50 3.03 2.94 2.97 3.12 3.16 3.11 3.31
ɫ҂ 3.43 3.35
(2.97–3.10) (2.90–2.99) (2.92–3.02) (3.10–3.24) (3.06–3.23) (3.02–3.19) (3.22–3.40) (3.38–3.48) (3.22–3.43)
R25 12.00 12.79* 12.64* 13.19 14.72* 14.06 14.24
ɫ҂ 16.3* 15.72*
(11.42–12.52) (12.51–13.91) (12.04–13.10) (12.71–13.95) (13.90–15.37) (13.43–14.32) (13.65–15.57) (15.17–17.68) (14.75–16.53)
PTV(P)
67.2 D98% (Gy) 35.7 35.8 35.8 35.7 35.7 35.7 35.6 35.6 35.6
(54.6–92.8) (35.6–36.0) (35.6–36.1) (35.6–35.9) (35.4–36.1) (35.6–36.1) (35.4–35.8) (35.5–35.7) (35.5–35.8) (35.3–35.75)
D2%(Gy) 41.9 41.9 41.9 42.0 41.9* 41.9 42.2
҂ 42.2 42.1
(41.9–42.0) (41.8–41.9) (41.8–42.0) (41.9–42.0) (41.8–41.9) (41.8–41.9) (42.0–42.3) (41.9–42.2) (41.9–42.3)
Abbreviations: FA full arc, PA300 300° partial arc, PA210 210° partial arc, HI homogeneity index, CI conformity index, CN conformation number, R50, R25 = intermediate and low dose spillage (evaluated for CTV(P)
receiving 40Gy), D98% = near minimum dose, D2% = near maximum dose. * = significantly different from 10 F plans (same arc arrangement), ɫ = significantly different from 10 F (FA) plans, ҂ = significantly different
from 10 F (PA300) plans
p ≤ 0.005 considered statistically significant (*, ɫ, ҂)
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Prostate only plans
Dosimetrically, all evaluated plans were highly conformal
CI = 1.17 − 1.18 and CN ≥ 0.91, Table 2. For FA plans, a
slight, but significant, increase in low-dose (R25) spillage
outside the PTV was observed in 6 F and 6MV flattened
beams plans compared to 10 F plans (p = 0.0020 in both
cases). The same trend was observed in partial arc plans
with significantly lower (R25) values for plans delivered
with 10 F photon beams. Compared to FA plans, 10 F
plans with partial 300° arcs also resulted in a slight
increase in the R50 and R25; (FA vs. PA300: 3.0 vs 3.1
(p = 0.0195) and 12.0 vs 13.2 (p = 0.0371), respectively).
PA210 plans had the highest intermediate- and low-
dose spillage outside PTV (FA vs. PA210; R50 3.03 vs. 3.31
(p = 0.0039) and R25 12.00 vs. 14.24 (p = 0.0039)). Table 4
shows OAR dose metrics resulting from using different
energies and beam arrangements.
Overall, only small dosimetric differences exist be-
tween the different plans. For PO plans, 10 F beams with
PA300 arcs were superior compared to other energies
and beam arrangements leading to significantly lower
doses to the rectum (mean dose and D50% for FA 10 F
vs. 10 F PA300: 16Gy vs. 14.4Gy (p = 0.0039) and 15.7Gy
vs. 14.2Gy (p = 0.002), respectively).
Prostate and pelvic lymph nodes plans
Only minor differences were observed between the differ-
ent PPLN plans in terms of PTV coverage, dose spillage
and doses to OAR as seen in Tables 3 and 5. It was not al-
ways possible to meet all OARs dose-volume constraints
adopted for PO plans, therefore minor relaxation of upper-
most bladder and rectum constraints were permitted. Inter-
active attempts were made to keep the OARs doses as low
as possible without jeopardising PTVs coverage (Fig. 1).
Comparing PO plans with PPLN plans, there was a
significant increase in the dose to OARs (10 F mean doses,
PO PA300 vs. PPLN 2PA300; bladder (4.1(2.4 − 8.7) Gy vs.
19.3(17.4 − 20.4) Gy), rectum (14.4(13.2 − 16.2) Gy vs.
18.4(16.7 − 19.7) Gy), Bowel (0.2(0.2 − 0.2) Gy vs. 8.4(5.9 −
11.5) Gy).
MUs and estimated delivery times
Highly significant differences in MUs and delivery times
emerged between plans when using different energies as
Table 3 Dose metrics for PTVs; median and ranges and statistical outcomes for different energies and arc arrangements for prostate
and pelvic nodes (PPLN) plans
Structure 2FA 2PA300
Volume (cc) 10 F 6 F 6MV 10 F 6 F 6MV
HI 1.05 1.05 1.05 1.05 1.05 1.05
(1.05–1.05) (1.05–1.05) (1.05–1.05) (1.05–1.05) (1.05–1.05) (1.05–1.05)
CI 1.21 1.21 1.22 1.23 ɫ 1.23 1.22
(1.20–1.22) (1.18–1.22) (1.20–1.22) (1.21–1.24) (1.21–1.24) (1.21–1.24)
CN 0.91 0.91 0.91 0.91 0.91 0.91
(0.89–0.92) (0.90–0.92) (0.91–0.92) (0.88–0.92) (0.89–0.92) (0.89–0.92)
R50 4.21 4.43* 4.50* 4.31 4.63* 4.64*
(4.06–4.39) (4.31–4.60) (4.42–4.67) (4.17–4.43) (4.48–4.81) (4.57–4.79)
R25 8.65 9.02* 9.19* 8.80 9.09 9.19*
(8.32–9.07) (8.63–9.63) (8.69–9.72) (8.48–9.24) (8.70–9.43) (8.83–9.81)
PTV(P)
67.2 D98% (Gy) 35.7 35.8 35.9 35.7 35.8 35.8
(54.6–92.8) (35.3–36.1) (35.4–36.0) (35.5–36.1) (35.3–36.0) (35.3–35.9) (35.4–35.9)
D2% (Gy) 42.0 42.0 42.0 42.0 42.0 42.1
(42.0–42.1) (42.0–42.1) (42.0–42.1) (42.0–42.1) (42.0–42.1) (42.0–42.1)
PTV(SV/LN)
796.2 D98%(Gy) 24.2 24.2 24.2 24.1 24.0 24.1
(746.4 − 855.9) (24.1–24.3) (24.1–24.2) (24.2–24.3) (24.0–24.2) (23.9–24.0) (24.1–24.3)
D2% (Gy)
¥ 26.6 26.6 24.7 26.6 26.7 26.7
(26.6–26.7) (26.5–26.7) (26.5–26.7) (26.6–26.8) (26.6–26.8) (26.6–26.8)
Abbreviations: FA full arc, PA300 300° partial arc, HI homogeneity index, CI conformity index, CN conformation number, R50, R25 intermediate and low dose spillage
(evaluated for PTV(SV/LN) receiving 25Gy), D98% = near minimum dose, D2%= near maximum dose. * = significantly different from 10 F plans (same arc arrangement),
ɫ = significantly different from 10 F (FA) plans. ¥ assessed for a structure [(PTV(SV/LN)) – (PTV(P) = 10 mm]
p ≤ 0.01 considered statistically significant (*, ɫ)
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shown in Fig. 2. Superior plans were obtained using 10 F
beams in terms of treatment time for both PO and PPLN
plans. This reduction was more pronounced in PO plans
where on average 73% (p = 0.002) and 43% (p = 0.002) re-
duction in treatment time was obtained when using 10 F
beams compared to 6MV and 6 F, respectively. Using
PA300 arcs, a further small but statistically significant re-
duction in treatment time was obtained (PA300 10 F vs.
FA10F: 57.4 ± 4.2 vs. 63.3 ± 2.3 seconds(s), p = 0.002). A
slight reduction in MUs was also observed in PA300 plans
Fig. 1 Population mean dose-volume histograms (DVHs) and standard deviation (shaded areas) for selected structures for 10 F plans. Left panel;
prostate only (PO) plans full arc (FA), partial 300° arcs (PA300) and 210° arcs (PA210). Right panel; Prostate and pelvic nodes (PPLN) plans 2FA,
2PA300 arcs
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Table 4 Dose metrics for OARs; median and ranges and statistical outcomes for different energies and arc arrangements for
prostate only (PO) plans
Structure FA PA300 PA210
Volume (cc) 10 F 6 F 6MV 10 F 6 F 6MV 10 F 6 F 6MV
Bladder Mean (Gy) 4.1 4.3 4.3* 4.1 4.2 4.0 4.4҂ 4.5* 4.6*
448.2 (2.6–8.7) (2.7–8.8) (2.7–8.8) (2.4–8.7) (2.6–8.7) (2.6–8.6) (2.5–9.0) (2.6–9.2) (2.6–9.2)
(234.3 − 566.0) D2cc(Gy) 40.0 40.1 40.1 40.3 40.2 39.8 40.0 39.9 39.9
(39.6–40.6) (39.4–40.5) (39.5–40.6) (39.4–40.6) (39.6–40.6) (39.5–40.2) (39.3–40.2) (39.4–40.3) (39.5–40.4)
D95% (Gy) 0.2 0.4* 0.3* 0.2 0.3* 0.3 0.2 0.3* 0.3*
(0.1–0.6) (0.2–0.8) (0.2–0.8) (0.1–0.6) (0.2–0.8) (0.2–0.8) (0.1–0.6) (0.2–0.9) (0.2–0.8)
D50% (Gy) 0.8 1.1 1.1 0.8 1.1 0.9 0.8 1.1 1.1
(0.6–2.6) (0.8–2.6) (0.8–2.8) (0.5–2.5) (0.8–2.4) (0.7–2.5) (0.5–2.5) (0.8–2.4) (0.7–2.5)
V18.1Gy (%) 8.4 8.1 8.4 8.3 8.5 7.8 9.8
ɫ҂ 9.7 10.0
(4.5–20.0) (4.4–19.9) (4.3–19.7) (4.2–20.3) (4.2–20.8) (4.2–20.3) (4.7–22.6) (4.6–23.4) (4.7–23.1)
V29Gy (%) 3.6 3.4 3.5* 3.7 3.6 3.0 4.0
҂ 4.0 4.0
(2.6–8.0) (2.5–7.8) (2.5–7.8) (2.4–7.8) (2.4–7.9) (2.5–7.9) (2.5–9.0) (2.5–9.0) (2.5–9.1)
V37Gy (cc) 7.4 7.5 7.5 7.5 7.4 6.6 7.1 7.1 7.2
(5.6–7.7) (5.5–7.9) (5.5–7.8) (5.6–7.8) (5.6–7.9) (5.0–7.7) (5.7–7.8) (5.6–7.5) (5.3–7.7)
Rectum Mean(Gy) 16.0 16.0 15.8 14.4 ɫ 14.7 14.3 15.1 ɫ 14.8 14.7
57.9 (14.1–16.9) (14.2–16.8) (14.1–17.0) (13.2–16.2) (13.1–16.4) (12.6–15.7) (13.2–16.7) (13.3–15.9) (13.3–16.4)
(53.8–72.2) D2cc (Gy) 35.6 35.7 35.7 35.6 35.6 35.0 35.8 35.9 35.8
(32.1–37.5) (32.0–37.3) (31.7–37.6) (32.6–37.6) (32.6–37.5) (31.5–37.1) (32.6–37.6) (33.3–37.5) (32.7–37.6)
D95% (Gy) 1.2 1.4 1.4* 1.1 1.4 1.4 1.2 1.4 1.4*
(1.0–1.9) (1.2–2.0) (1.3–2.2) (1.0–1.9) (1.2–2.0) (1.3–1.7) (1.0–2.1) (1.2–2.0) (1.2–2.1)
D50% (Gy) 15.7 15.7 15.3 14.2
ɫ 13.9 13.4 14.3 ɫ 13.4 13.7
(14.7–17.0) (14.5–17.0) (14.8–16.8) (11.4–14.9) (11.7–15.6) (11.3–15.0) (12.7–15.7) (12.5–14.6) (12.2–15.7)
V18.1Gy (%) 38.6 38.7 38.1 34.0 34.2 33.8 34.6
ɫ 30.6 31.1
(34.7–43.5) (34.8–43.1) (33.6–43.1) (30.1–39.1) (29.8–38.8) (26.3–37.5) (29.1–39.3) (27.6–37.7) (28.3–39.7)
V29Gy (%) 12.1 11.8 11.7 11.0 11.5 10.8 11.2 11.2 11.4
(6.6–15.4) (6.3–15.3) (6.1–15.1) (7.2–16.2) (7.1–15.0) (6.2–14.2) (6.6–15.6) (7.4–15.9) (6.9–15.8)
V36Gy (cc) 1.9 1.9 1.9 1.9 1.9 1.2 2.0 2.0 2.0
(0.6–2.7) (0.7–2.7) (0.6–2.7) (0.6–2.7) (0.8–2.7) (0.6–2.4) (0.9–2.8) (0.9–2.8) (0.8–2.8)
V38Gy (cc) 0.7 0.7 0.7 0.6 0.6 0.4 0.7 0.8 0.7
(0.1–1.3) (0.1–1.2) (0.1–1.3) (0.1–1.3) (0.1–1.3) (0.1–1.0) (0.2–1.3) (0.2–1.3) (0.2–1.4)
Sigmoid Mean (Gy) 0.6 0.8* 0.8* 0.6 0.8* 0.8 0.6 0.8* 0.8*
106.1 (89.5–156.8) (0.3–0.9) (0.4–1.0) (0.4–1.0) (0.3–0.9) (0.4–1.0) (0.4–1.0) (0.3–0.9) (0.4–1.0) (0.4–1.0)
Bowel Mean (Gy) 0.1 0.2* 0.2* 0.2 0.2* 0.2 0.1 0.2* 0.2*
255.2 (95.1–376.9) (0.1–0.2) (0.2–0.3) (0.1–0.2) (0.2–0.2) (0.1–0.2) (0.1–0.2) (0.1–0.2) (0.2–0.2) (0.1–0.2)
Rt Fem Mean (Gy) 5.7 6.1 6.3 7.1 7.3 6.3 7.8 ɫ҂ 8.0 8.0
52.6 (51.1–57.5) (4.8–6.6) (4.7–7.9) (4.7–8.1) (5.3–8.1) (5.3–8.2) (4.8–8.0) (7.0–8.6) (6.8–9.1) (6.2–8.7)
Lt Fem Mean (Gy) 6.4 6.5 6.1 6.6 7.1 6.5 7.4 7.8 7.4
55.1 (50.5–57.5) (4.5–7.7) (4.8–7.4) (4.6–8.2) (5.0–7.6) (5.8–7.9) (5.1–8.6) (5.5–8.5) (5.6–9.2) (5.8–9.0)
Urethra V42Gy (%) 0.1 0.1 0.0 3.1 0.0 0.0 5.6 1.3 3.0
0.4 (0.3–0.6) (0.0–5.5) (0.0–0.4) (0.0–4.3) (0.0–6.8) (0.0–5.0) (0.0–3.7) (0.0–40.6) (0.0–9.0) (0–21.0)
NV Bundle V38Gy (%) 32.2 33.7 31.5 27.3 33.6 27.0 24.9 40.2 40.0
0.8 (0.3–2.4) (15.8–42.7) (19.5–41.4) (18.2–47.0) (14.8–39.7) (19.3–41.2) (18.7–38.8) (9.4–45.2) (39.0–40.7) (39.0–41.0)
Abbreviations: FA full arc, PA300 300° partial arc, PA210 210° partial arc, D2cc the dose received by the hottest 2 cc (near maximum dose), DX% the dose received by X%
of the volume, VXGy the volume receiving dose XGy. Rt right, Lt left, Fem femoral head, NV Neurovascular,
* = significantly different from 10 F plans (same arc arrangement),
ɫ= significantly different from 10 F (FA) plans, ҂= significantly different from 10 F (PA300) plans
p ≤ 0.005 considered statistically significant (*, ɫ, ҂)
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Table 5 Dose metrics for OARs; median and ranges and statistical outcomes for different energies and arc arrangements for
prostate and pelvic nodes (PPLN) plans
Structure 2FA 2PA300
Volume (cc) metric 10 F 6 F 6MV 10 F 6 F 6MV
Bladder Mean (Gy) 19.1 19.1 19.3 19.3 19.5 19.3
448.2 (17.0–20.3) (17.2–20.3) (17.0–20.4) (17.4–20.4) (18.1–20.3) (17.6–20.2)
(234.3 − 566.0) D2cc (Gy) 39.4 39.4 39.5 39.5 39.3 39.3
(38.8–40.0) (38.9–40.0) (38.9–40.1) (39.1–40.0) (39.0–40.0) (39.1–40.0)
D95% (Gy) 9.5 10.4 10.6 10.1 10.8 10.8
(8.3–10.8) (8.7–11.1) (8.4–11.7) (7.5–11.6) (8.1–11.5) (8.4–11.7)
D50% (Gy) 18.5 18.3 18.4 18 18.1 17.9
(15.7–19.6) (15.9–19.5) (15.8–19.4) (16.5–19.6) (17.0–19.8) (16.5–19.2)
V18.1Gy (%) 51.3 50.2 50.6 49.4 49.8 48.9
(38.3–57.4) (37.3–57.7) (37.2–57.0) (42.8–61.7) (44.3–60.5) (42.2–57.7)
V37Gy (cc) 7.2 6.9 6.8 7.1 6.9 6.5
(4.9–7.5) (5.0–7.5) (4.6–7.6) (5.8–7.5) (5.1–7.3) (5.1–7.5)
Rectum Mean (Gy) 18.6 18.7 18.7 18.4 18.4 18.5
57.9 (16.9–19.7) (16.7–19.4) (16.9–19.7) (16.7–19.7) (16.7–19.8) (16.7–19.8)
(53.8–72.2) D2cc (Gy) 34.8 34.7 34.7 34.8 34.9 34.8
(31.2–36.0) (30.7–36.0) (30.6–35.9) (31.1–36.0) (31.3–36.1) (30.8–36.0)
D95% (Gy) 3.7 3.8 4.1* 4.1 4.0 4.5
(1.7–7.3) (2.2–6.9) (2.5–7.5) (1.8–7.7) (2.3–7.3) (2.6–7.6)
D50% (Gy) 17.2 17.2 17.1 17.4 17.1 17.3
(16.0–18.6) (16.0–18.4) (16.1–18.3) (15.9–18.2) (15.9–18.2) (16.0–17.9)
V18.1Gy (cc) 45.4 45.2 45.3 46.7 45.5 45.9
(40.1–52.0) (39.9–51.2) (41.1–50.6) (40.2–49.8) (39.9–50.1) (41.1–49.0)
V29Gy (%) 11.6 12.2 11.9 11.1 11.2 11.3
(6.0–17.8) (5.4–16.4) (5.3–17.3) (6.1–18.4) (6.1–18.4) (6.0–18.9)
V36Gy (cc) 1.0 1.1 1.0 1.1
ɫ 1.1 1.1
(0.3–2.0) (0.2–2.1) (0.2–2.0) (0.5–2.2) (0.3–2.1) (0.2–2.1)
V38Gy (cc) 0.1 0.1 0.1 0.1 0.1 0.1
(0.0–0.3) (0.0–0.3) (0.0–0.2) (0.0–0.3) (0.0–0.3) (0.0–0.3)
Sigmoid Mean (Gy) 18.7 18.7 18.7 19.1 19.2 18.9
106.1 (12.5–20.4) (12.6–20.3) (12.8–20.1) (12.5–20.4) (12.7–20.8) (13.1–20.5)
(89.5–156.8) V18.1Gy (cc) 58.5 57.5 56.8 59.3 59.7 59.1
(36.3–67.1) (33.6–65.7) (35.3–64.4) (36.3–67.1) (36.1–69.7) (37.8–67.2)
Bowel Mean (Gy) 9.3 9.5 9.1 8.4 8.4 8.2
255.2 (6.1–11.5) (6.1–11.7) (6.3–11.7) (5.9–11.5) (6.2–11.7) (6.4–11.8)
(95.1–376.9) V15Gy (cc) 38.8 40.6 35.9 46.9 42.7 42.2
(5.6–80.1) (5.4–82.5) (3.8–82.0) (7.2–70.7) (8.7–80.6) (7.1–74.8)
V20Gy (cc) 10.0 11.0 9.4 11.9 10.9 11.9
(2.4–29.7) (2.3–30.5) (0.9–29.6) (2.4–31.4) (2.9–33.9) (2.6–33.4)
V22.5Gy (cc) 5.5 5.5 5.3 5.8 5.7 5.4
(1.5–16.1) (1.4–16.1) (0.4–16.1) (1.3–17.9) (1.7–17.3) (1.5–16.7)
V25Gy (cc) 1.3 1.5 1.4 1.7 1.3 1.8
(0.5–2.4) (0.4–2.5) (0.1–2.5) (0.3–3.6) (0.6–3.2) (0.5–2.9)
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(10 F PA300 vs. 10 F FA: 2195 ± 87 vs. 2362 ± 27 MUs) but
was found insignificant.
As shown in Fig. 2, the mean MUs and delivery times
for 2FA PPLN plans were; 2312 ± 102 and 120.0 ± 1.9 s
for 10 F beams, 2423 ± 115 and 125.3 ± 3.8 s for 6 F
beams, 2046 ± 97 s and 204.6 ± 9.7 s for 6MV beams, re-
spectively. For PPLN plans, 6MV plans had the lowest
number of MUs compared to FFF beams; this did not
however, translate into shorter treatment times due to
the limitation of the maximum dose rate associated with
6MV beams (600MU/min). In terms of treatment time,
PPLN 10 F and 6 F plans were equivalent and both
more efficient than plans delivered using 6MV beams
(10 F vs 6 F vs 6MV: 120 vs. 125 vs. 205 s, respectively).
Compared to 2FA plans, a further 15.6% and 12.7% re-
duction in treatment time was obtained when using
partial 10 F and 6 F arcs (2PA300), respectively.
Patient specific QA
Results of gamma analysis for a subset of plans are pre-
sented Fig. 3, (60 plans; PA300 plans for PO and PPLN
for all energies investigated, also see Additional file 1:
Appendix III for results obtained using the OCTAVIUS
1000 SRS array (30 PO plans)). Gamma passing rates
were slightly lower in PPLN compared to PO plans;
however, all plans were dosimetrically accepted using
our clinical acceptance thresholds as shown in Fig. 3.
Table 5 Dose metrics for OARs; median and ranges and statistical outcomes for different energies and arc arrangements for
prostate and pelvic nodes (PPLN) plans (Continued)
Rt Fem Mean (Gy) 10.4 11.1 11.1 10.4 11.1* 10.2
52.6 (51.1–57.5) (10.2–11.2) (10.5–11.3) (10.7–11.5) (9.2–11.1) (9.4–11.3) (9.3–11.3)
Lt Fem Mean (Gy) 10.5 10.8 10.9 9.9 10.4* 10.3*
55.1 (50.5–57.5) (9.7–11.1) (10.1–11.4) (10.6–11.5) (9.1–11.0) (9.2–11.9) (9.5–11.4)
Penile B V29.5Gy (cc) 3.2 3.1 3.5* 3.3 3.1 3.4
3.4 (2.3–4.4) (1.7–8.6) (2.1–8.5) (2.4–8.8) (1.7–8.4) (2.1–8.0) (2.4–8.5)
Urethra V42Gy (%) 3.6 0.5 0.7 1.4 5.7 0.6
0.4 (0.3–0.6) (0.0–14.6) (0.0–10.4) (0.0–7.4) (0.0–16.7) (0.0–13.2) (0.0–27.0)
NV Bundle V38Gy (%) 35.8 34.7 33.7 25.5 28.0 26.5
0.8 (0.3–2.4) (7.7–45.8) (4.9–45.5) (9.3–42.2) (9.8–42.7) (12.4–41.8) (11.9–42.1)
Abbreviations: FA full arc, 2PA300 300° partial arcs, D2cc the dose received by the hottest 2 cc (near maximum dose), DX% the dose received by X% of the volume,
VXGy = the volume receiving dose XGy. Rt right, Lt left, Fem femoral head, Penile B penile bulb, NV Neurovascular,
* = significantly different from 10 F plans (same
arc arrangement), ɫ = significantly different from 10 F (FA) plans
p ≤ 0.01 considered statistically significant (*, ɫ)
Fig. 2 Population mean and standard deviation (error bars) for the estimated delivery times (upper panel) and monitor units (lower panel) for all
plans investigated
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Discussion
In this study, we systematically evaluated and compared
the use of 10 F, 6 F, and 6MV photon beams for SABR-
VMAT PO and PPLN planning. Our results demonstrate
that it is feasible to treat the prostate with/without pelvic
nodes using flattened and un-flattened photon beams.
Optimal plans were obtained using FFF beams in terms
of the low-dose bath outside the PTVs and significantly
shorter treatment times for both PO and PPLN plans.
For PO, 10 F plans using partial 300° arcs were superior
to other energies and beam arrangements, leading to sig-
nificantly lower rectal doses with the shortest treatment
time. This came at the expense of a slight increase in the
R50 and R25 compared to FA plans. No further reduction
in treatment time or OAR doses was observed when
using 210° arcs, and a further significant increase in dose
spillage outside the PTV was present. In PPLN plans,
only minor differences in the low-dose region were ob-
served between 10 F and 6 F plans, although both were
superior to 6MV plans for all arc arrangements. Once
more, 2PA300 resulted in dosimetrically equivalent plans
and shorter treatment time compared to 2FA plans in
both 10 F and 6 F plans.
In a recent planning study, VMAT plans for patients
with different body habitus (n = 40) were generated using
6MV and 10MV flattened beams for PPLN (54Gy in 30
fractions) [13]. The authors concluded that 10MV plans
were better, providing faster dose falloff, and this im-
provement increased linearly with increasing patient
size. In this current study, only minor differences (clinic-
ally insignificant) were observed in plans quality using
10 F and 6 F photons for PPLN (Tables 3 and 5 and
Additional file 1: Appendix I for further analysis).
Several studies have shown that using a single VMAT
arc in PO plans is favoured over two arcs, being dosime-
trically equivalent and requiring shorter treatment times
[7, 8]. Shorter delivery times minimize the risk of intra-
fraction motion which is highly relevant, especially in
the SABR settings. A class solution with a single partial
arc of 210° for prostate only VMAT-SABR was proposed
by Murray et al. (6MV, 42.7Gy in 7 fractions) [7]. Com-
pared to FA plans, 210° arcs plans had reduced rectal
dose, MUs and estimated treatment times [7]. The dif-
ferent optimal arc of PA300 proposed in the present
study could be due to the different planning system/
Linacs used (Elekta vs Varian). In an investigation of the
use of FFF single arc vs. dual arcs VMAT techniques for
low-, intermediate- and high-risk prostate cancer, Fortin
et al. also favoured the use of a single arc (FA) in all
risk groups planned (10 F, 36.25Gy in 5 fractions) [8].
However, their definition of CTV for high-risk patients
was the prostate + lower 2 cm SV and did not include
PLN, once more making their plans equivalent to our
presented PO plans. Despite the differences between
Fig. 3 Results of pre-treatment patient specific QA gamma analysis (PTW OCTAVIUS 729 2D array). Mean gamma passing rate and standard
deviation for 3%/3 mm (upper panel) and 2%/2 mm (lower panel) global gamma analysis 300° partial arcs plans for PO and PPLN delivered
with different photon energies
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our study and the available literature [7, 8], good agree-
ments were found in target coverage, conformity and
OAR doses.
As reported in the literature [10] and confirmed in
this study, the major advantage of using un-flattened
photon beams in SABR-VMAT over flattened beams is
the considerable reduction in treatment time. Using our
proposed class solutions, a delivery time of less than a
minute was required for PO plans, while PPLN plans were
delivered in less than two minutes. Similar treatment
times were reported by Fortin et al. [8] for PO plans using
10 F single and dual VMATarcs.
In a clinical investigation of 5 fractions SABR (40Gy to
prostate and 25Gy to PLN) with brief androgen suppres-
sion (12 months) for high-risk prostate cancer, Bauman
et al. reported higher than anticipated late rectal toxicity
that led to trial termination after recruiting 16 patients
[11]. High rates of acute (26%) and late (60%) grade 2
toxicity were observed. Four patients (26%) experienced
late grade 3 GI toxicity and one patient (7%) developed
a grade 4 GI toxicity. In their protocol, 25Gy was pre-
scribed to (lymph node + 5 mm isotropic margin) and
40Gy to the (prostate + 1 cm proximal SV + 5 mm).
The authors acknowledged the limitations of their
study and suggested that several confounding factors;
specific frail elderly patient group, contouring on CT
scans alone, large high-dose PTV, relaxed OARs con-
straints, lack of image guidance and manual registration
with no fiducial markers were among the candidate factors
for such high toxicities. In their letter to editors, Kishan et
al. argued that the high toxicity reported by Bauman et al.
[11] originated neither from the prostate being pre-
scribed 40Gy nor the inclusion of the PLN, as their pre-
liminary results in a similar study with a different
design, suggests that both approaches were well toler-
ated by their patient group [17]. In a recent study (the
largest of its kind) of predictive parameters for rectal
bleeding grade 2 or higher in prostate SABR, multivari-
ate modelling revealed that the rectal volume receiving
≥38Gy (EQD2Gy = 80.6Gy for αβ ¼ 3 ) is a strong pre-
dictor for high grade haematochezia [18]. In our study,
despite the increased rectal doses in PPLN compared
to PO plans, only negligible rectal volumes received
38Gy (0.0 − 0.3 cc), which is well below the 2 cc recom-
mended threshold [18].
Emerging results from several clinical trials of dose es-
calation with SABR (35Gy − 50Gy in 5 fractions) show
excellent biochemical control and low to moderate late
toxicities [19–22]. This is also confirmed by the early re-
sults from the ongoing SATURN SABR trial including
lymph nodes for high-risk prostate [23]. In the SPORT
trial design, after initial CT scanning, patients will have
three gold seed fiducial markers for image-guidance. From
our experience and also as noted from the literature, the
biggest challenge in SABR is to meet bladder and rectal
dose constraints. For each patient, a polyethylene glycol
hydrogel spacer will be inserted under trans-rectal
ultrasound guidance which will potentially lead to
further rectal dose reduction [24, 25]. Simulation CT
and MRI scans will then be acquired and fused for
contouring.
As discussed by Marino et al [26], treatment plan
quality could also be influenced by several other factors
related to setting priorities to create the right balance
between PTV coverage and OAR sparing. Personal
knowledge of treatment planning systems and the ex-
perience of the planner are among the factors affecting
the quality of treatment plans. Using a class solution for
planning will provide a simple method to address these
problems and optimize treatment planning for SABR
prostate. Further improvements in creating more con-
sistent high quality plans with minimal work load
could be anticipated when using advanced methods,
e.g. knowledge-based (semi-automated) planning [27],
multi-criteria optimization [28], plan quality assurance
models and/or systems capable of fully automated
treatment planning [29].
To the best of our knowledge, this is the first study to
investigate an optimal SABR-VMAT planning class solu-
tion for prostate and pelvic lymph nodes. The efficacy of
several arc arrangements and different photon beam en-
ergies was assessed and class solutions are presented. To
achieve the anticipated theoretical benefits of SABR
without introducing unnecessary toxicity risk, strict pro-
tocols should be set and followed to control and
minimize treatment uncertainty and to ensure the deliv-
ery of the dose levels accepted at planning. Potentially
lower rectal doses could be achieved by using anatomy
modifiers; however, it is more difficult to reduce bladder
doses further, especially when the lymph nodes are
electively irradiated. Therefore, short and long term
follow-up is warranted to enable a full assessment of
each treatment arm.”
Conclusions
Treatment plans using FFF photon beams required
shorter delivery times and demonstrated reduced dose
spillage outside the PTV compared to plans obtained
using flattened beams. A class solution employing a sin-
gle 300° partial arc with 10 F photons is optimal for
SABR-VMAT for prostate only. Two 300° partial arcs of
either 6 F or 10 F photon beams are equally optimal to
deliver acceptable plans for prostate and pelvic lymph
node SABR-VMAT. Caution must be applied when plan-
ning exceptionally large patients as the proposed class
solution may not be optimal.
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Additional files
Additional file 1: A study of plan quality robustness with varying
patient size: Table S1-Table S3: Figure S2- Figure S5. (DOCX 29 kb)
Additional file 2: Figure S1. Population mean dose-volume histograms
(DVHs) and standard deviation (shaded areas) for selected structures for
full arc (FA) plans using different energies. Left panel: prostate only (PO)
single FA plans. Right panel: prostate and pelvic nodes (PPLN) dual full
arc (2FA) plans. (PDF 350 kb)
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